Compass Therapeutics, Inc. (CMPX)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Licensing revenue | - | - | 850 | |
| Research and development | 16,415 | 8,612 | 11,174 | |
| General and administrative | 4,651 | 3,627 | 4,721 | |
| Total operating expenses | 21,066 | 12,239 | 15,895 | |
| Loss from operations | -21,066 | -12,239 | -15,045 | |
| Other income | 1,185 | 1,758 | 1,969 | |
| Us-gaap_incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest | - | - | -13,076 | |
| Net loss | -19,881 | -10,481 | -13,076 | |
| Unrealized loss on marketable securities | 18 | 577 | -1 | |
| Comprehensive loss | -19,863 | -9,904 | -13,077 | |
| Net loss per share - basic and diluted (in dollars per share) | -0.14 | -0.08 | -0.1 | |
| Us-gaap_weightedaveragenumberofsharesoutstandingbasic | 138,282,000 | 137,589,000 | 137,589,000 | |